



## Solid Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option

January 30, 2018

CAMBRIDGE, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "SLDB"), announced today the closing of its initial public offering of 8,984,375 shares of its common stock, sold by the Company at a public offering price of \$16.00 per share. This includes the exercise in full by the underwriters of their overallotment option to purchase up to 1,171,875 additional shares of common stock from the Company at the same price. Including the proceeds from the sale of these additional shares, the Company received total net proceeds of approximately \$133.7 million from the offering, after deducting the underwriting discounts and commissions, but before deducting estimated offering expenses.

J.P. Morgan, Goldman Sachs & Co. LLC and Leerink Partners acted as joint book-running managers of the offering, and Nomura and Chardan acted as co-managers for the offering.

The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from:

J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or by email: [prospectus-req\\_fi@jpmchase.com](mailto:prospectus-req_fi@jpmchase.com); Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, fax: 212-902-9316, email: [prospectusgroup-ny@ny.email.gs.com](mailto:prospectusgroup-ny@ny.email.gs.com); or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by telephone at (800) 808-7525, ext. 6132 or by email at [syndicate@leerink.com](mailto:syndicate@leerink.com).

A registration statement relating to the offering has been filed with, and declared effective by, the United States Securities and Exchange Commission ("SEC"). Copies of the registration statement can be accessed through the SEC's website at [www.sec.gov](http://www.sec.gov). This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

### About Solid Biosciences

Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. The company's lead candidate, SGT-001, is an adeno-associated viral (AAV) vector-mediated gene therapy, which is currently under investigation in a Phase I/II clinical trial called IGNITE DMD.

### Contact Information:

Solid Biosciences  
Kate Niazi-Sai  
617-337-4680  
[media@solidbio.com](mailto:media@solidbio.com)

Chris Brinzey  
Westwicke Partners  
339-970-2843  
[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)

Source: Solid Biosciences Inc.